Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Director/PDMR Shareholding

8 Mar 2019 15:59

RNS Number : 3629S
Synectics PLC
08 March 2019
 

Synectics plc

(the "Company" or the "Group")

 

Award of Options under Share Plan

 

Directorate / PDMR Shareholding

 

8 March 2019

 

Synectics plc (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, announces that on 7 March 2019 it made awards over 65,000 Synectics plc ordinary shares of 20p (the "Shares") to certain Persons Discharging Managerial Responsibility ("PDMRs"), under its Performance Share Plan ("PSP"), as detailed below:

 

 

Name

Position

Status

PSP award (number of Shares)

Paul Webb

Chief Executive

Executive Director

25,000

Simon Beswick

Finance Director

Executive Director

20,000

David Lowe

Business Strategy Director

PDMR

20,000

 

Following these awards, their total interests in Shares comprise:

 

 Name

 Shares held

Interest in Shares in Synectics plc share schemes

Resultant total interest in Shares

% of issued share capital

Paul Webb

36,322

276,923

313,245

1.76

Simon Beswick

-

20,000

20,000

0.11

David Lowe

10,000

20,000

30,000

0.17

 

Under the PSP, selected employees are entitled to exercise an option to receive a certain number of Shares at any time after a 3 year vesting period, at no cost to themselves. The number of Shares that are awarded at the end of the 3 year period is dependent on the achievement of certain performance criteria.

 

Vesting of the PSP awards is dependent on the total return on Shares compared with the AIM All Share Total Return Index (the "Index"). If the total return on Shares out-performs the Index by 5% or more in the 3 years following the award, all of the Shares awarded will vest. If Shares match the Index performance, then 25% of the awarded Shares will vest. Between these points the number of Shares that vest will be pro-rata. If the total return on Shares underperforms the Index, then no Shares will vest. The limit on the number of Shares over which interests may be awarded remains unchanged.

 

Any entitlement under the PSP will lapse on cessation of employment prior to the end of the 3 year vesting period, unless cessation of employment is by reason of redundancy, ill health or death.

 

Should the performance criteria be met in full or part, it is intended that the appropriate number of Shares will be satisfied from unallocated Shares already held within the Company's employee benefit trust.

 

Full details of the PSP were set out in the Company's Annual Report for the year ended 30 November 2017.

 

For further information, please contact:

 

Synectics plc

Claire Stewart, Company Secretary

Tel: +44(0) 114 255 2509

 

Stockdale Securities

Tom Griffiths / Henry Willcocks

Tel: +44 (0) 20 7601 6100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEASDPESKNEFF
Date   Source Headline
8th Jun 20267:00 amRNSEBT Share Purchase
1st Jun 20261:48 pmRNSEBT Share Purchase
20th May 20267:00 amRNSFunding of EBT to Acquire Ordinary Shares and RPT
18th May 202612:48 pmRNSResult of AGM
18th May 20267:01 amRNSBoard Change
18th May 20267:00 amRNSAGM Trading Update
23rd Apr 20261:30 pmRNSCorrection to Notice of Annual General Meeting
14th Apr 20267:00 amRNSPosting of Annual Report & Accounts, Notice of AGM
13th Mar 20262:05 pmRNSDirector dealings
12th Mar 20267:00 amRNSDirector Dealings
9th Mar 202610:20 amRNSDirector Dealings
3rd Mar 20263:30 pmRNSDirector / PCA Dealings
3rd Mar 20267:00 amRNSFinal Results and Strategic Update
24th Feb 202612:15 pmRNSNotice of Final Results and Investor Presentation
23rd Feb 20267:00 amRNSOngoing New Business Momentum
19th Feb 20261:41 pmRNSHolding(s) in Company
19th Jan 20269:00 amRNSHoldings in Company
18th Dec 202510:00 amRNSHolding(s) in Company
17th Dec 20257:00 amRNSFull Year Trading Update
24th Nov 20257:00 amRNS-RExtension of Framework Agreement with Stagecoach
3rd Nov 20257:00 amRNS£1.8 million contract with Bus Eireann
16th Oct 20257:01 amRNSNew Contracts - Traction in Broader Energy Sector
16th Oct 20257:01 amRNSTrading Update
16th Oct 20257:00 amRNSAppointment of Nominated Adviser and Sole Broker
9th Oct 202512:16 pmRNSDirector dealings
2nd Oct 20257:00 amRNSPDMR dealings
2nd Sep 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSPDMR dealings
16th Jul 20257:00 amRNSLeisure & Hospitality Contract Wins
8th Jul 20257:00 amRNSHalf-year Report
19th Jun 20257:00 amRNSAppointment of Chief Financial Officer
9th Jun 20257:00 amRNSTrading Update and Notice of Results
4th Jun 20257:00 amRNSUS$4.8m Contract Extension
21st May 20257:00 amRNSPDMR Dealings
12th May 20257:00 amRNS£1.1 million Contract Award
7th May 20251:00 pmRNSResult of Annual General Meeting
7th May 20257:00 amRNSAGM Trading Update
2nd Apr 20257:00 amRNSPDMR dealings
1st Apr 20257:00 amRNSPosting of Annual Report & Accounts, Notice of AGM
31st Mar 20257:00 amRNS£2.0 million Award
4th Mar 20257:00 amRNSFinal Results
14th Feb 20257:00 amRNSNotice of Final Results and Investor Presentation
27th Jan 20257:00 amRNS$2.2 million Contract Award
13th Jan 20255:30 pmRNSHoldings in Company
6th Jan 20258:40 amRNSHoldings in Company
6th Jan 20258:30 amRNSHoldings in Company
9th Dec 20241:30 pmRNSHoldings in Company
9th Dec 20247:00 amRNSTrading Update
5th Dec 20247:00 amRNS$2.7 million Contract Awards
27th Nov 20247:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.